Entyvio vs Remicade: Two Different Philosophies for Treating IBD

Entyvio (vedolizumab) and Remicade (infliximab) are both IV-infused biologics used to treat ulcerative colitis and Crohn’s disease, but they represent fundamentally different treatment strategies. Entyvio works selectively in the gut by blocking immune cells from entering intestinal tissue, while Remicade suppresses TNF-alpha throughout the entire body. This distinction shapes their safety profiles, how fast they work, and which patients benefit most from each.

Two Approaches to the Same Disease

When a gastroenterologist recommends biologic therapy for inflammatory bowel disease, the conversation often begins with a philosophical fork in the road. One path says: turn down the entire immune system’s inflammatory response, including the molecule TNF-alpha that drives damage in the gut (and in joints, skin, and other places). The other path says: leave the systemic immune system alone, and instead block the specific trafficking of immune cells into the intestinal wall.

Remicade has been the workhorse of IBD treatment since its approval in 1998. It belongs to the TNF-inhibitor class and works powerfully and quickly. Entyvio, approved in 2014, takes the targeted approach. It is sometimes called “gut-selective” because its effects are largely confined to the gastrointestinal tract.

Neither approach is inherently superior. The best choice depends on disease severity, how urgently symptoms need to be controlled, what other conditions a patient has, and what treatments have already been tried.

How Each Drug Works

Remicade (Infliximab)

Remicade is a chimeric monoclonal antibody that binds to tumor necrosis factor-alpha (TNF-alpha), a signaling protein that promotes inflammation. By neutralizing TNF-alpha throughout the body, Remicade reduces inflammation not only in the gut but everywhere. This is why it also treats rheumatoid arthritis, psoriasis, and ankylosing spondylitis.

Entyvio (Vedolizumab)

Entyvio blocks the alpha-4-beta-7 integrin on immune cells. This integrin acts like a homing signal that directs certain white blood cells to the gut lining. By blocking this signal, Entyvio prevents those immune cells from reaching and accumulating in the intestinal tissue — without affecting immune function elsewhere in the body.

Efficacy and the VARSITY Trial

The VARSITY trial, published in 2019, was the first head-to-head trial comparing two biologics for ulcerative colitis. The results showed that Entyvio achieved higher rates of clinical remission and mucosal healing than adalimumab (Humira, another TNF inhibitor) at week 52.

However, VARSITY compared Entyvio to Humira — not directly to Remicade. Many gastroenterologists consider Remicade to be the strongest TNF inhibitor for IBD, particularly for Crohn’s disease. So while VARSITY provided useful evidence, it does not settle the Entyvio-vs-Remicade debate definitively.

What clinical experience and real-world data suggest:

• For ulcerative colitis: Entyvio and Remicade are considered roughly comparable in moderate disease. Many GI specialists now lean toward Entyvio as a first-line biologic for UC because of its favorable safety profile.
• For Crohn’s disease: Remicade is often preferred for severe or fistulizing Crohn’s, where rapid and powerful immune suppression is needed. Entyvio is used but may take longer to show benefit.
• For patients with extraintestinal manifestations (joint pain, skin lesions, eye inflammation): Remicade’s systemic action can address these simultaneously, while Entyvio typically does not.

Infusion Schedule

One practical advantage of Entyvio that patients appreciate: the 30-minute infusion time. For someone who has been on Remicade’s 2-hour infusions, switching to Entyvio can feel like getting part of the day back.

Side Effect Profiles

Remicade

• Infusion reactions (fever, chills, chest tightness), especially after drug holidays or missed doses
• Increased risk of serious infections, including tuberculosis (TB screening is mandatory before starting)
• Small increased risk of lymphoma and other malignancies with long-term use
• Rare: drug-induced lupus, liver injury, demyelinating disease

Entyvio

• Generally well tolerated; most common side effects are headache, joint pain, and nasopharyngitis
• Lower infection risk compared to TNF inhibitors because immune suppression is localized to the gut
• Rare risk of progressive multifocal leukoencephalopathy (PML), though no confirmed cases have occurred with Entyvio alone
• Infusion reactions are uncommon and typically mild

The Anti-Drug Antibody Problem

One challenge that is particularly relevant to Remicade is the development of anti-drug antibodies (ADAs). Because Remicade is a chimeric antibody (part mouse, part human), the immune system can learn to recognize it as foreign and produce antibodies against it. This can lead to:

• Loss of response over time (the drug stops working)
• More frequent or severe infusion reactions
• The need for dose escalation or shorter intervals, which increases cost

Co-administration of an immunomodulator like azathioprine or methotrexate is often used with Remicade to reduce ADA formation. This combination therapy is well-supported by evidence but adds another medication with its own side effects.

Entyvio has a much lower rate of immunogenicity. Anti-drug antibody formation is uncommon, and loss of response due to ADAs is rare. This means Entyvio can usually be given as monotherapy without an immunomodulator, which some patients and doctors see as an advantage.

Step Therapy and Insurance

Many insurance plans require step therapy for biologics, meaning patients must try and fail a less expensive treatment before the insurer will approve the preferred drug. For IBD, this often means trying a TNF inhibitor (or its biosimilar, like Inflectra) before gaining access to Entyvio.

This can be frustrating when a gastroenterologist believes Entyvio is the better first choice for a specific patient. Appeals and peer-to-peer reviews with the insurer are sometimes necessary. Documenting why the doctor prefers Entyvio — for example, a patient’s history of recurrent infections or concern about systemic immunosuppression — strengthens these appeals.

Cost-wise, both drugs are expensive at list price. Remicade’s availability as biosimilars (Inflectra, Renflexis, Avsola) has pushed its effective cost down in many cases. Entyvio does not yet have a biosimilar, which can make it the more expensive option depending on insurance contracts. Understanding whether a drug falls under the medical or pharmacy benefit matters, as copay structures differ significantly.

Side-by-Side Comparison

Which Might Be Right

The decision often comes down to urgency and complexity:

• Severe, rapidly progressing, or fistulizing disease: Remicade’s faster onset and systemic potency make it the more common choice when things need to improve quickly.
• Moderate UC without extraintestinal issues: Entyvio’s safety profile and the VARSITY data increasingly make it a first-line option.
• Patients with infection concerns: Entyvio’s gut-selective action means less systemic immunosuppression, which matters for patients with a history of serious infections or who are older.
• Patients who have lost response to a TNF inhibitor: Switching mechanism classes to Entyvio is a well-established strategy.
• Patients with joint or skin involvement alongside IBD: Remicade addresses both gut and extraintestinal symptoms simultaneously.

What rarely gets discussed openly: some patients develop a strong emotional attachment to whichever drug pulled them out of a flare. That is valid. But if the disease changes, the treatment plan sometimes needs to change too. A good gastroenterologist will revisit the biologic choice periodically, not just set it and forget it.